Literature DB >> 10411153

Bowen disease and risk of subsequent malignant neoplasms: a population-based cohort study of 1147 patients.

A B Jaeger1, A Gramkow, H Hjalgrim, M Melbye, M Frisch.   

Abstract

OBJECTIVE: To address the long-standing question of whether patients with Bowen disease are at increased risk of internal malignant neoplasms. PATIENTS: A total of 1147 Danish patients diagnosed between 1978 and 1993 as having Bowen disease at nongenital sites were followed up for 6463 person-years for cancer occurrence up to 16 years after the skin lesion. MAIN OUTCOME MEASURE: Standardized incidence ratios (SIRs)--the ratios of observed-to-expected numbers of cancer--served as measures of relative risk.
RESULTS: The observed number of noncutaneous cancers occurring in the cohort (n = 115) was close to expected (n = 103.0) (SIR = 1.1; 95% confidence interval, [CI], 0.9-1.3). However, nonmelanoma skin cancer (SIR = 4.3; 95% CI, 3.5-5.4; n = 83), lip cancer (SIR = 8.2; 95% CI, 2.6-19.1; n = 5), and, among men, leukemia (SIR = 3.2; 95% CI, 1.04-7.5; n = 5) occurred in excess.
CONCLUSIONS: Patients with Bowen disease do not appear to constitutionally be at any unusually high general cancer risk. The increased risk of invasive skin and lip cancers is likely due to the common risk factor of UV light.

Entities:  

Mesh:

Year:  1999        PMID: 10411153     DOI: 10.1001/archderm.135.7.790

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  13 in total

1.  Assessment of Cutaneous Squamous Cell Carcinoma (cSCC) In situ Incidence and the Risk of Developing Invasive cSCC in Patients With Prior cSCC In situ vs the General Population in the Netherlands, 1989-2017.

Authors:  Selin Tokez; Marlies Wakkee; Marieke Louwman; Eline Noels; Tamar Nijsten; Loes Hollestein
Journal:  JAMA Dermatol       Date:  2020-09-01       Impact factor: 10.282

2.  Predictors for cutaneous basal- and squamous-cell carcinoma among actinically damaged adults.

Authors:  J A Foote; R B Harris; A R Giuliano; D J Roe; T E Moon; B Cartmel; D S Alberts
Journal:  Int J Cancer       Date:  2001-01-20       Impact factor: 7.396

3.  Is a personal history of nonmelanoma skin cancer associated with increased or decreased risk of other cancers?

Authors:  Anthony J Alberg; Alexander H Fischer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-03       Impact factor: 4.254

Review 4.  Nonmelanoma skin cancer and the risk of second primary cancers: a systematic review.

Authors:  Lee Wheless; Joshua Black; Anthony J Alberg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-06-22       Impact factor: 4.254

5.  Premalignant neoplasms and squamous cell carcinoma of the anal margin.

Authors:  Aalok Sahai; Ira J Kodner
Journal:  Clin Colon Rectal Surg       Date:  2006-05

6.  The combined influence of oral contraceptives and human papillomavirus virus on cutaneous squamous cell carcinoma.

Authors:  Jimmy T Efird; Amanda E Toland; C Suzanne Lea; Christopher J Phillips
Journal:  Clin Med Insights Oncol       Date:  2011-03-27

Review 7.  Interventions for cutaneous Bowen's disease.

Authors:  Fiona J Bath-Hextall; Rubeta N Matin; David Wilkinson; Jo Leonardi-Bee
Journal:  Cochrane Database Syst Rev       Date:  2013-06-24

8.  A case of Bowen's disease and small-cell lung carcinoma: long-term consequences of chronic arsenic exposure in Chinese traditional medicine.

Authors:  Linda Lee; Gwyn Bebb
Journal:  Environ Health Perspect       Date:  2005-02       Impact factor: 9.031

9.  Recurrent Bowen's disease of scalp treated with high dose rate surface mold brachytherapy: a case report and review of the literature.

Authors:  Ajeet Kumar Gandhi; Macharla Anjaneyulu Laviraj; Lakhan Kashyap; Suvendu Purkait; Daya Nand Sharma; Pramod Kumar Julka; Goura Kishor Rath
Journal:  J Contemp Brachytherapy       Date:  2014-12-31

10.  Human papillomavirus infection and p16 expression in the immunocompetent patients with extragenital/extraungual Bowen's disease.

Authors:  Marián Švajdler; Roman Mezencev; Jana Kašpírková; Denisa Kacerovská; Dmitry V Kazakov; Ondrej Ondič; Michal Michal
Journal:  Diagn Pathol       Date:  2016-06-24       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.